Bayer Deal History & Licensing Activity
Bayer is a large pharma headquartered in Germany. Over the past three years, Bayer has been involved in 13 licensing and acquisition transactions, with a primary focus on PROTACs (4 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
10
Active Trials
50
Top Modality
PROTACs
Focus Area
Solid Tumors
Bayer Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Bayer in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| AB-1009 | Genethon | Gene Therapy | Phase 1 | license | Apr 2026 |
| Anti-CD47-501 | Apollomics | PROTACs | Phase 3 | option | Nov 2025 |
| Nectin-4-tinib | IGM Biosciences | RNAi | Phase 3 | license | Aug 2025 |
Bayer Pipeline Focus
Therapeutic areas and modalities where Bayer is most active based on deal history and clinical trial data.
Therapeutic Areas
Bayer Strategic Signals
Key indicators of Bayer's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Bayer Clinical Pipeline
Bayer has 50 active clinical trials across 6 development phases.
19
Unknown
3
Phase 4
4
Not Applicable
6
Phase 1
8
Phase 2
10
Phase 3
See How Your Asset Matches Bayer's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
PROTACs Benchmarks
Upfront, milestone, and royalty benchmarks for protacs deals
RNAi Benchmarks
Upfront, milestone, and royalty benchmarks for rnai deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Bayer Licensing & Deal Activity
Bayer is a large pharma company based in Germany that has been actively engaged in licensing transactions across the biopharma landscape. With 13 deals over the past three years, Bayer ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Bayer include Solid Tumors (14 deals and trials), Cardiovascular (12 deals and trials), Oncology (10 deals and trials), and Metabolic (7 deals and trials). In terms of modality, Bayer has shown particular interest in protacs, rnai, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Bayer and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Bayer's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.